NEW YORK (GenomeWeb News) – Spartan Biosciences today announced Appleton Medical will distribute its CYP2C19 testing platform in the central US.
The Spartan RX CYP2C19 System received 510(k) clearance from the US Food and Drug Administration in August. It provides test results from a cheek swab in less than one hour, and aids physicians in prescription decisions involving drugs metabolized by the CYP450 2C19 genetic pathway. They include anti-platelet drugs, beta blockers, and proton pump inhibitors.
Financial and other terms of the deal were not disclosed.
The test was CE marked as an in vitro diagnostic in late 2010, and Spartan has inked deals with several distributors for the test in Europe.